Does Regence Cover Wegovy?

Regence covers Wegovy for weight loss on commercial plans only where the employer has purchased anti-obesity drug coverage. Regence does not publish drug-level Wegovy formulary detail, so you cannot confirm from a public document — use the Regence drug-lookup tool at regence.com and confirm with your HR department. If the employer excluded weight-loss drugs, no PA will be approved regardless of medical need.

Regence operates in Oregon, Washington, Idaho, and Utah. State matters primarily for Medicaid: each state has its own GLP-1 obesity coverage rules, and only 13 states covered GLP-1s for obesity in Medicaid as of January 2026. For commercial plans across all four states, the deciding factor is the same: whether your employer opted into the anti-obesity benefit. Verify on the state-specific Regence plan formulary.

Regence Medicare plans cannot cover Wegovy for weight loss — that is a federal statutory exclusion affecting all Medicare Part D plans. Regence Medicare Advantage can cover Wegovy for the cardiovascular risk-reduction indication in members with established CVD who are overweight or obese, with prior authorization. The Medicare GLP-1 Bridge ($50/month, launching July 1, 2026) offers weight-loss access outside Part D for eligible beneficiaries.

No. Regence does not publish specific Wegovy prior-authorization criteria in a publicly accessible document. The baseline PA standard for weight-loss GLP-1s — BMI 30 or higher, or 27 with a comorbidity, plus documented lifestyle program and 5% weight-loss renewal — is the industry norm, but Regence's specific criteria must be verified through the plan's drug-lookup tool or by calling member services.

It depends on the denial reason. A prior-authorization denial on medical-necessity grounds is appealable — you can submit additional clinical documentation. A benefit exclusion (the employer carved out anti-obesity drugs) is generally not appealable through the standard PA process, because the drug category is not in the plan. Ask your insurer to specify in writing whether the denial is a medical-necessity determination or a benefit exclusion before deciding whether to appeal.